As billions in drug patents expire, the pharmaceutical industry faces a looming patent cliff. Biotech innovators must rethink IP protection to safeguard revenue and innovation. This article explores trade secrets, continuous filings, data ownership, and regulatory exclusivity, strategies that help companies adapt and thrive beyond patent loss.

Strong patents aren't always enough. In biotech and pharma, success hinges on how well your IP tells a story. Learn why great inventions fail in the market, how to craft a compelling IP narrative, and what investors and licensing partners really want to hear. Discover Hylton-Rodic Law’s approach to building winning patent strategies.